Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 157-167 , March 2006

Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange

  • Bruce C. McLeod, MD (Professor of Medicine and Pathology, Rush Medical College; Director of the Blood Center, Rush University Medical Center)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 312 942 6865; Fax: +1 312 942 2824.

References 

  1. McLeod BC. Introduction to the third special issue: clinical applications of therapeutic apheresis. J Clin Apheresis. 2000;15:1–5
  2. Tullis JL. Albumin 1. Background and use. JAMA. 1977;237:355–360
  3. Finlayson JS. Albumin products. Semin Thromb Hemost. 1980;6:85–120
  4. Mateytschuk P, Dash CH, Gascoigne EW. Production of human albumin solutions: a continually developing colloid. Br J Anaesth. 2000;85:887–895
  5. Chopek M, McCullough J. Protein and biochemical changes during plasma exchange. In:  Berkman EM,  Umlas J editor. Therapeutic Hemapheresis. Washington, DC: American Association of Blood Banks; 1980;p. 13–52
  6. Weinstein R. Basic principles of therapeutic blood exchange. In:  McLeod BC,  Price TH,  Weinstein R editor. Apheresis: Principles and Practice. 2nd edn. Bethesda, MD: AABB Press; 2003;p. 295–320
  7. McClelland DLC. Safety of human albumin as a constituent of biologic therapeutic products. Transfusion. 1998;38:690–699
  8. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion. 1999;39:1160–1168
  9. Baxter Healthcare Corporation. Entry for Buminate 5%. Physician's Desk Reference, 58th edn. Montvale, NJ: Thomson PDR, 2004, pp 812–813.
  10. Stafford CT, Lobel SA, Fruge BC, et al. Anaphylaxis to human serum albumin. Ann Allergy. 1988;61:85–88
  11. Pool M, McLeod BC. Pyrogen reactions to human serum albumin in plasma exchange. J Clin Apheresis. 1995;10:81–84
  12. Pierce LR, Gaines A, Finlayson JS, Varricchio F, Epstein J. Hemolysis and acute renal failure due to the administration of albumin diluted in sterile water. Transfusion. 1999;39:110–111
  13. Vincent J-L, Wilkes MM, Navickis RJ. Safety of human albumin—serious events reported worldwide in 1998-2000. Br J Anaesth. 2003;91:625–630
  14. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomized controlled trials. Br Med J. 1998;317:235–240
  15. Wilkes MM, Navickis RJ. Patient survival after human albumin administration: a mete-analysis of randomized, controlled trials. Ann Intern Med. 2001;135:149–164
  16. Finfer S, Bellomo R, Boyce N, et al. For the SAFE study collaborators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256
  17. Owen HG, Brecher ME. Atypical reactions associated with the use of angiotensin-converting enzyme inhibitors with apheresis. Transfusion. 1994;34:891–894
  18. Verresen L, Waer M, Vanrenterghem Y, Michielsen P. Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet. 1990;316:1360–1362
  19. Imré Corporation, Special PMA supplement P850020, 3/12/93.
  20. Olbricht CJ, Schaumann D, Fischer DL. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors. Lancet (letter). 1995;340:908–909
  21. Alving BM, Hojima Y, Pisano JJ, et al. Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction. N Engl J Med. 1978;299:66–70
  22. Silberstein LE, Naryshkin S, Haddad JJ, Strauss JFIII. Calcium homostasis during therapeutic plasma exchange. Transfusion. 1986;26:151–155
  23. Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J Clin Apheresis. 1994;9:1–5
  24. Weinstein R. Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid. J Clin Apheresis. 1996;11:204–210
  25. Goss GA, Weinstein R. Pentastarch as partial replacement fluid for therapeutic plasma exchange: effect on plasma proteins, adverse events during treatment, and serum ionized calcium. J Clin Apheresis. 1999;14:114–121
  26. McLeod BC, Price TH, Owen H, et al. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion. 1999;39:282–288
  27. Norda R, Berseus O, Stegmayr B. Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. Transfus Apheresis Sci. 2001;25:33–41
  28. Korach JM, Guillevin L, Pettipas D, et al. Apheresis registry in France: indications, techniques and complications. Ther Apher. 2000;4:207–210
  29. In:  Brecher ME editors. Technical Manual. 14th edn. Bethesda: American Association of Blood Banks; 2002;p. 165
  30. O'Neill EM, Rowley J, Hansson-Wicher M, et al. Effect of 24-hour whole blood storage on plasma clotting factors. Transfusion. 1999;39:488–491
  31. Raphael JC. for the French Cooperative Group on Plasma Exchange in Guillain Barré syndrome. Efficacy of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987;22:753–761
  32. Pearl RG, Rosenthal MH. Metabolic alkalosis due to plasmapheresis. Am J Med. 1985;79:391–393
  33. Rock GA, Shumak KH, Buskard NA, et al. For the Canadian Apheresis study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325:393–397
  34. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578–1584
  35. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594
  36. Winters JL, Pineda AA, McLeod BC, Grima KM. Therapeutic apheresis in renal and metabolic disorders. J Clin Apheresis. 2000;15:53–73
  37. In:  Brecher ME editors. Technical Manual. 14th edn. Bethesda: American Association of Blood Banks; 2002;p. 166
  38. Moake JL. Thrombotic thrombocytopenic purpura. Thromb Haemost. 1995;74:240–245
  39. The North American TTP Group , Zeigler ZR, Shadduck RK, Gryn JF, et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura. J Clin Apheresis. 2001;16:19–22
  40. Horowitz B, Bonomo R, Prince AM, et al. Solvent/Detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 1992;79:826–831
  41. McLeod B, Gregory SA. Solvent/detergent plasma replacement in a highly plasma allergic patient with TTP. J Clin Apheresis. 2001;16:98;[abstract]
  42. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion. 1999;39:479–487
  43. Flamholz R, Jeon HR, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses?. J Clin Apheresis. 2000;15:169–172
  44. de Jonge J, Groenland TH, Metselaar HJ, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma. Anesth Anal. 2002;94:1127–1131
  45. Peters T. Serum albumin. In:  Putnam FW editors. The Plasma Proteins. vol. 1:New York: Academic Press; 1975;p. 133–181
  46. Putnam FW. In:  Putnam FW editors. Transferrin. 2nd edn. The Plasma Proteins. vol. 1:New York: Academic Press; 1975;p. 266–316
  47. Roberts HR, Monroe DM, Hoffman M. Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In:  Beutler E,  Lichtman MA,  Coller BS,  Kipps TJ,  Seligsohn U editor. Williams Hematology. 6th edn. New York: McGraw-Hill; 2001;p. 1409–1431

PII: S1521-6926(05)00005-8

doi: 10.1016/j.beha.2005.01.004

Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 157-167 , March 2006

Article Tools